Atopic Dermatitis – Ready for a Transformative Phase!

Intense clinical activity may completely transform atopic dermatitis (AD) space over the next decade as per GlobalData – the leading data and Analytics Company.

Atopic dermatitis, also known as eczema, is an inflammatory skin disorder characterized by red and itchy skin. The condition is quite common and chronic in children and tends to flare up periodically.

Atopic Dermatitis / Eczema - Causes - Symptoms - Diagnosis - Treatment - FAQs
Atopic dermatitis is an inflammatory, non-contagious, chronic skin disorder that involves scaly and itchy rashes. It is also called eczema, dermatitis or atopy.

‘Numerous drug developments for atopic dermatitis (AD) that are under various clinical trials may completely transform the drug market of the disease over a decade. ’

Tweet it Now

Although there are drugs to treat symptomatically, there is no complete cure for atopic dermatitis. The current progress in the drug realm of AD may however bring a revolutionary change in the market.

It is noted that almost 64% of the drugs in development for atopic dermatitis are small molecular agents and the rest 36% of the AD drug market under progress is contributed by biologics.

“The AD space has seen a dramatic rise in interest from the pharmaceutical industry, which is exemplified by the sheer size of its clinical development pipeline. An increasing number of companies are seeing the potential in this indication for its return on investment, and are entering the space singularly or through strategic partnerships. The introduction of unique drug classes to the AD space will provide patients with a plethora of options and will give doctors more choice although this may come with further scrutiny especially for the JAK class,” says Ramla Salad, a Pharma Analyst at GlobalData.

How Allergens Get on Our Nerves: Atopic Dermatitis
Atopic dermatitis affects the daily lives of nearly 20 percent of kids and up to 5 percent of adults. The condition can have a big impact on the quality of life of these patients.

The Great Leap of Progress

The data notes that various products are under clinical development at different stages within the seven major markets (7MM*) for AD. This may mark huge progress in the treatment efficacy of the disease.

Postpartum Depression in Moms May Up Atopic Dermatitis Risk in Kids
Children born to mothers with postpartum depression are more likely to suffer a chronic skin condition called atopic dermatitis (AD) throughout childhood and adolescence.

There are almost 35% of the pipeline agents in Phase I trials, 55% in Phase II, and 10% in Phase III trials of clinical development.

The small molecule agents include multiple late-stage JAK inhibitors (AbbVie’s Rinvoq – upadacitinib, Pfizer’s abrocitinib and Asana Bioscience’s gusacitinib) and PDE4 inhibitors (Otsuka, Medimetriks’ difamilast and Arcutis Biotherapeutics’ Pharmaceutical/ roflumilast) for topical use in AD.

New Therapeutic Approach Discovered to Treat Atopic Dermatitis
Newly discovered therapeutic approach shows promise to treat skin diseases such as atopic dermatitis, reveals a new study.

On the other hand, the biologics include notaby the late-stage interleukin (IL) inhibitors like AbbVie’s risankizumab (anti-IL-23), Galderma’s nemolizumab (anti-IL-31), Eli Lilly’s lebrikizumab (anti-IL-13) and Janssen’s bermekimab (anti-IL-1).

All these biologics are administered subcutaneously. Among various drugs, Dupixent marks the highest uptake in AD with global reported sales of over $4bn in 2020.

Other Drugs in Pipeline

The other advancements in the drug advancement for AD include:

The biologic OX40 inhibitors and small molecule sphingosine 1-phosphate receptor (S1PR) modulators – ground-breaking development.
Kyowa Kirin/Amgen’s KHK-4083 for Phase III assessment, Kymab’s KY-1005 and Ichnos Sciences’ telazorlimab under Phase II trials.
New oral therapy that includes Arena Pharmaceutical’s etrasimod for Phase the – first-in-class agent.

“Although injections may not be preferred by some, they can be an attractive option for patients because they are administered less frequently (every two to four weeks), which could increase compliance. However, topical creams could prove popular in the pediatric group due to the ease of application,” says Salad.

Source-Medindia